Keywords: merck, fosamax, news, co, bisphosphonate, drug, alendronate

Merck: Fosamax news

Article | 30 October 1995

- Merck & Co's bisphosphonate drug Fosamax (alendronate) can increase bone mineral density in post-menopausal women with osteoporosis, according to two studies ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Merck

Merck KGaA

Go to company listing

Related Drugs

Alendronate Sodium

Fosamax

Go to drug listing